Clinical Trials

Passionately Committed to Patients

Our purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. The evaluation of the safety and efficacy of our investigational medicines in clinical trials is a critical component of the development process. We appreciate the role of volunteers who enroll in clinical trials, because they help us better understand the potential benefits and risks of our investigational therapies.

Active Clinical Trials

Below is a selection of some of our clinical trials. Use the filters to find those of interest to you.

Can't find what you are looking for? See a full list of our clinical trials on ClinicalTrials.gov

 

A Phase 2b/3 set of studies to evaluate the efficacy and safety of induction and maintenance therapy with TD-1473 in subjects with moderately-to-severely active ulcerative colitis with up to 60 weeks of treatment. 

A 3-year multi-center, Long-Term Safety (LTS) study to evaluate the safety and tolerability of TD-1473 in subjects with ulcerative colitis who have participated in the maintenance study (RHEA).

A Phase 2 study to evaluate the efficacy, safety and tolerability of TD-1473 in subjects with moderately-to-severely active Crohn's disease with up to 60 weeks of treatment.

A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic neurogenic Orthostatic Hypotension (snOH) with up to 4 weeks of treatment.

A Phase 3, 22-week, multi-center, randomized withdrawal study of ampreloxetine (TD-9855) in treating symptomatic neurogenic Orthostatic Hypotension (snOH) in subjects with primary autonomic failure.

A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic neurogenic Orthostatic Hypotension (snOH) over 26 weeks.